Plain-English translation of NCT04068155 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new treatment called diffusing alpha emitters radiation therapy (DaRT), which uses tiny radioactive seeds placed directly into skin cancer tumors. The seeds release radiation that attacks cancer cells from the inside. Researchers want to see if this treatment is safe and effective at shrinking skin cancers over about 9 to 11 weeks.
Standard radiation therapy and other skin cancer treatments don't work for everyone, and some people have tumors that come back or don't respond well. This trial exists to see if this new approach — delivering radiation directly inside the tumor with seeds — could offer a better option for people with certain types of skin cancer.
You likely qualify if…
You likely don't qualify if…
If you join this trial, doctors will insert small radioactive seeds directly into your skin tumor during a procedure. You will then be monitored over the following 9 to 11 weeks to check how well the tumor shrinks and to watch for any side effects. The study team will measure your tumor size and ask you about any symptoms or concerns you experience during this time.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
France
Sponsor
Alpha Tau Medical LTD.
Enrollment target
~80 participants
Started
April 2022
Primary completion
January 2025
This trial's estimated completion date has passed — the record may not be fully up to date.
Age range
18 Years and older
Last updated on clinicaltrials.gov in November 2024.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Liron Dimnik
Centre Leon Berard
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.